BACKGROUND: Gigantomastia during pregnancy is exceedingly rare, with an incidence of 1/28,000-100,000 pregnancies. Treatment during pregnancy is a dilemma, and postpartum reduction mammoplasty remains the mainstay of treatment. CASE: Massive bilateral breast enlargement occurred at 19 weeks of gestation in a 24-year-old woman, gravida 2, and led to ulceration and sloughing. Conservative management with bromocriptine resulted in healing of the ulcers and resolution of symptoms. After six months of bromocriptine therapy postpartum, marked involution of the breasts occurred without recurrence. CONCLUSION: Prolonged bromocriptine therapy should be given after delivery to a pregnant woman with gigantomastia during pregnancy before planning surgical reduction mammoplasty.
BACKGROUND:Gigantomastia during pregnancy is exceedingly rare, with an incidence of 1/28,000-100,000 pregnancies. Treatment during pregnancy is a dilemma, and postpartum reduction mammoplasty remains the mainstay of treatment. CASE: Massive bilateral breast enlargement occurred at 19 weeks of gestation in a 24-year-old woman, gravida 2, and led to ulceration and sloughing. Conservative management with bromocriptine resulted in healing of the ulcers and resolution of symptoms. After six months of bromocriptine therapy postpartum, marked involution of the breasts occurred without recurrence. CONCLUSION: Prolonged bromocriptine therapy should be given after delivery to a pregnant woman with gigantomastia during pregnancy before planning surgical reduction mammoplasty.
Authors: Anna Kasielska-Trojan; Marian Danilewicz; Jerzy Strużyna; Magdalena Bugaj; Bogusław Antoszewski Journal: Arch Med Sci Date: 2019-09-26 Impact factor: 3.707
Authors: Shadi Rezai; Jenna T Nakagawa; John Tedesco; Annika Chadee; Sri Gottimukkala; Ray Mercado; Cassandra E Henderson Journal: Case Rep Obstet Gynecol Date: 2015-12-02